PATENT CLAIM ANALYSIS

Application Number: 16031250
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "360000"]

Abstract:
Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Claim (Index 67):
A pharmaceutical composition for use in treating a mental disorder in a human patient comprising an effective amount of riluzole in pharmaceutical dosage form in combination with at least one pharmaceutically acceptable carrier for administration via oral, buccal, vaginal, rectal or topical route of administration.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 95.0
- Lexical Diversity: 1.67391
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14278573', '11399188', '11591244', '13887901', '14022804']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7578557304712477
- 35 USC 102 Novelty (BERT): 0.6020278728852936
- Combined Prediction Score: 0.7422729447126523
- Mean Citation Score: 389.055668
- Max Citation Score: 599.818
- Similarity Product: 439.2917231948376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test